We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$33.6M
Cap. Flow
+$4.33M
Cap. Flow %
3.64%
Top 10 Hldgs %
74.7%
Holding
51
New
6
Increased
12
Reduced
5
Closed
18

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.09M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.05M
3
PFE icon
Pfizer
PFE
+$1.5M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$1.35M
5
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$1.29M

Top Sells

Rank Stock Value
1
QLTI
QLT Inc
QLTI
+$3.48M
2
HNT
HEALTH NET INC
HNT
+$3.4M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$951K
4
BAX icon
Baxter International
BAX
+$736K
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$570K

Sector Composition

Rank Sector Weight
1 Miscellaneous 52.77%
2 Healthcare 47.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXX
51
CALL
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
– –
-3,125
Closed -$2.11M
1 2
3

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Healthcare Value Capital held 51 positions worth $119M, down 22% from $153M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Healthcare Value Capital deployed $4.33M of net new capital in Q2 2014, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, down from 65% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Vaxart, an estimated $380K trimmed.

  • Healthcare Value Capital's largest Q2 2014 buy was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.
  • Healthcare Value Capital added most to AstraZeneca in Q2 2014, an estimated $3.09M increase.
  • Healthcare Value Capital's biggest Q2 2014 reduction was Vaxart, cutting an estimated $380K.
  • Healthcare Value Capital fully exited QLT Inc in Q2 2014, selling an estimated $3.48M.
  • Healthcare Value Capital's ten largest holdings make up 75% of its $119M portfolio in Q2 2014.
  • Healthcare Value Capital opened 6 new positions and closed 18 in Q2 2014.
  • Healthcare Value Capital's portfolio value fell 22% quarter-over-quarter to $119M.

Based on Healthcare Value Capital's 13F filing for Q2 2014, filed 13 Aug 2014.